Intellia Therapeutics, Inc. (NTLA) SEC Filings & Earnings Calls

Regulatory risk remains until PDUFA date; FDA could still issue CRL or require additional data.

“BLA under review; no advisory committee planned but approval not guaranteed.”

Commercial execution risk if approved; first-in-class therapy requires market education and reimbursement.

“If approved, would be first in vivo CRISPR therapy; new modality adoption risk.”

Debt service obligations and restrictive covenants; milestone-dependent additional funding.

“Risks associated with Intellia’s indebtedness, including its debt-service obligations, restrictive covenants, security interests and the potential for default; the possibility that Intellia and OrbiMed will not mutually agree to make the additional $100 million available.” · word for word

Nex-z Phase 3 trials resumed after genomic analysis revealed HLA allele association with liver transaminase elevations.

“The analysis revealed that the highest observed liver transaminase elevations were in patients carrying one specific human leukocyte antigen (HLA) allele” · word for word

Litigation risk

“'BlueAllele Corp. v. Intellia Therapeutics, Inc. ... alleges infringement by the Company of various patents ... seeks unspecified compensatory damages and an injunction.'”

Dependence on collaboration revenue

“Collaboration revenue declined 46% YoY; deferred revenue reduced to zero.”

Clinical hold on nex-z Phase 3 trials

“the ability to resume dosing in the MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials following removal of the clinical hold placed by the U.S. Food and Drug Administration (FDA) on their Investigational New Drug (IND) applications” · word for word

Litigation risk

“BlueAllele Corp. v. Intellia Therapeutics, Inc. ... alleges infringement by the Company of various patents ... seeks unspecified compensatory damages and an injunction.”

Securities class action lawsuit

“Gonzalez v. Intellia Therapeutics, Inc. ... alleges claims under Sections 10(b) and 20(a) and Rule 10b-5 ... premised upon statements relating to the Company's NTLA-3001 program.”

Net loss continues, though reduced R&D spend. Reliance on successful commercialization of lonvo-z.

“Net loss was $96.2 million” · word for word

Regulatory and commercial risks for lonvo-z and nex-z programs.

“Rolling BLA submission; clinical holds lifted for nex-z trials”

FDA clinical hold on nex-z trials

“the impact of the clinical holds that the FDA placed on the MAGNITUDE and MAGNITUDE-2 Phase 3 trials in October 2025.” · word for word

Reliance on single product launch for near-term value

“Our ability to report data from our HAELO Phase 3 clinical trial of lonvoguran ziclumeran ('lonvo-z') for the treatment of hereditary angioedema ('HAE'), file and gain approval of a biologics license application ('BLA') for lonvo-z, and successfully launch lonvo-z for HAE in the first half of 2027.” · word for word

High cash burn rate

“Net loss of $412.7 million in 2025.”

Clinical hold risk resolved for MAGNITUDE, but residual safety monitoring and exclusion criteria remain.

“Mitigation measures include enhanced liver monitoring, steroid guidance, and exclusion of patients with certain liver abnormalities or recent cardiovascular instability.”

Clinical Hold and Safety Risk

“On October 29, 2025, the FDA placed a clinical hold on the investigational new drug (IND) applications for the MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials for patients with ATTR-CM and ATTRv-PN, respectively.” · word for word

Regulatory Approval Uncertainty

“We will need to resolve the clinical hold with the FDA in order to resume dosing and screening in MAGNITUDE.” · word for word

Commercialization Risk

“We have never generated any revenue from product sales and our ability to generate revenue from product sales and become profitable depends significantly on our success in a number of areas.” · word for word

MAGNITUDE Phase 3 trial for nex-z in ATTR-CM remains on clinical hold, creating uncertainty for the program.

“Intellia's engagement with FDA is ongoing regarding the clinical hold on the IND for the MAGNITUDE Phase 3 clinical trial of nex-z for patients with ATTR-CM.” · word for word

Cash burn rate: cash decreased from $861.7M to $605.1M over FY2025, indicating significant operating cash consumption.

“Cash, cash equivalents and marketable securities were $605.1 million as of December 31, 2025, compared to $861.7 million as of December 31, 2024.” · word for word

Clinical hold on MAGNITUDE trial for ATTR-CM remains; uncertainty on path forward.

“FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 clinical trial in ATTR-CM.” · word for word

Grade 4 liver transaminases and increased total bilirubin observed in a patient, leading to clinical holds.

“following the observation of Grade 4 liver transaminases and increased total bilirubin in a patient who was dosed with nex-z in MAGNITUDE that met the trial’s protocol-defined pausing criteria.” · word for word

Clinical holds on MAGNITUDE and MAGNITUDE-2 trials remain unresolved.

“resolving the clinical holds on the MAGNITUDE and MAGNITUDE-2 trials of nex-z for the treatment of ATTR amyloidosis and finalizing a plan with regulators on the path forward.” · word for word

FDA clinical hold on Phase 3 trials

“MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials... currently on clinical hold by the U.S. Food and Drug Administration (FDA)” · word for word

FDA clinical hold after patient death; potential for trial termination or significant delay; regulatory risk high.

“FDA placed a clinical hold... patient who experienced Grade 4 liver transaminase elevations... passed away”

Pipeline concentration risk; nex-z is key asset; clinical hold may impair value significantly.

“suspended its milestone guidance for nex-z pending regulatory alignment” · word for word

High cash burn and reliance on capital markets

“Net cash used in operating activities $325.5 million for the nine months ended September 30, 2025.”

Litigation risk (patent infringement and securities class action)

“BlueAllele Corp. v. Intellia Therapeutics, Inc. filed July 8, 2024 alleging patent infringement. Gonzalez v. Intellia Therapeutics, Inc. filed February 11, 2025 alleging securities law violations.”

Dependence on collaboration revenue

“Collaboration revenue is primarily from Regeneron agreements; termination of SparingVision and ReCode agreements reduces diversification.”

Share dilution from ATM offerings

“Issued 10.3 million shares in Q3 2025 alone through ATM offerings, raising $114.5 million.”

Clinical hold on lead pipeline asset nex-z; potential for significant delay or termination of development program.

“FDA placed a clinical hold on the Investigational New Drug applications for the MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials for nexiguran ziclumeran ('nex-z').”

Serious adverse event (Grade 4 liver transaminases and increased total bilirubin) raises safety concerns for nex-z.

“Grade 4 liver transaminases and increased total bilirubin in a patient who was dosed with nex-z in the MAGNITUDE trial.” · word for word

Uncertainty regarding ability to resume trials and eventual regulatory approval; potential impact on stock price and investor confidence.

“The Company intends to work with the FDA to address the clinical hold as expeditiously as possible.” · word for word

Lead asset nex-z clinical hold due to severe liver toxicity; potential for program termination or significant delay

“Grade 4 liver transaminases and increased total bilirubin in a patient dosed with nex-z; trial paused per protocol” · word for word